Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice
Publication
, Conference
Choi, SJ; Yi, J; Tedder, TF; Koeberl, DD; Kishnani, PS; Sun, B
Published in: MOLECULAR THERAPY
2021
Duke Scholars
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
2021
Volume
29
Issue
4
Start / End Page
361 / 361
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Choi, S. J., Yi, J., Tedder, T. F., Koeberl, D. D., Kishnani, P. S., & Sun, B. (2021). Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice. In MOLECULAR THERAPY (Vol. 29, pp. 361–361).
Choi, Su Jin, John Yi, Thomas F. Tedder, Dwight D. Koeberl, Priya S. Kishnani, and Baodong Sun. “Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice.” In MOLECULAR THERAPY, 29:361–361, 2021.
Choi SJ, Yi J, Tedder TF, Koeberl DD, Kishnani PS, Sun B. Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice. In: MOLECULAR THERAPY. 2021. p. 361–361.
Choi, Su Jin, et al. “Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice.” MOLECULAR THERAPY, vol. 29, no. 4, 2021, pp. 361–361.
Choi SJ, Yi J, Tedder TF, Koeberl DD, Kishnani PS, Sun B. Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice. MOLECULAR THERAPY. 2021. p. 361–361.
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
2021
Volume
29
Issue
4
Start / End Page
361 / 361
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences